Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash & Equivalents: 2015-2019

Historic Cash & Equivalents for Outlook Therapeutics (OTLK) over the last 5 years, with Sep 2019 value amounting to $8.0 million.

  • Outlook Therapeutics' Cash & Equivalents rose 70.77% to $24.0 million in Q2 2020 from the same period last year, while for Jun 2020 it was $24.0 million, marking a year-over-year increase of 70.77%. This contributed to the annual value of $8.0 million for FY2019, which is 366.73% up from last year.
  • Latest data reveals that Outlook Therapeutics reported Cash & Equivalents of $8.0 million as of FY2019, which was up 366.73% from $1.7 million recorded in FY2018.
  • Outlook Therapeutics' 5-year Cash & Equivalents high stood at $9.1 million for FY2015, and its period low was $1.7 million during FY2018.
  • Moreover, its 3-year median value for Cash & Equivalents was $3.2 million (2017), whereas its average is $4.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 74.07% in 2016, then skyrocketed by 366.73% in 2019.
  • Outlook Therapeutics' Cash & Equivalents (Yearly) stood at $9.1 million in 2015, then crashed by 74.07% to $2.4 million in 2016, then surged by 35.45% to $3.2 million in 2017, then slumped by 46.09% to $1.7 million in 2018, then skyrocketed by 366.73% to $8.0 million in 2019.